Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (131-140 of 220) with videos related to

Pageof 22
Sort By:
Antiviral Therapy|February 2, 2012
Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in SpainEva Poveda, Eugenia Vispo, Pablo Barreiro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2006
Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3Pablo Barreiro, Luz Martín-Carbonero, Marina Núñez, et al.
Antiviral Therapy|March 9, 2005
Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4Vincent Soriano, Marina Núñez, Matilde Sánchez-Conde, et al.
Antiviral Therapy|June 26, 2014
Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapiesPablo Labarga, Jose V Fernández-Montero, Mariola López, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 23, 2008
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovirCarmen de Mendoza, Inmaculada Jiménez-Nacher, Carolina Garrido, et al.
Hepatology International|June 6, 2022
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in SpainJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|November 24, 2015
New hepatitis C therapies for special patient populationsVincent Soriano, Pablo Labarga, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|May 6, 2016
Prevention and management of treatment failure to new oral hepatitis C drugsLaura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, et al.
Alimentary Pharmacology & Therapeutics|November 2, 2022
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in SpainJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Antiviral Therapy|August 5, 2008
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2bEugenia Vispo, Pablo Barreiro, Sonia Rodriguez-Nóvoa, et al.
Pageof 22

Showing results (131-140 of 220) with videos related to

Sort By:
Pageof 22
Antiviral Therapy|February 2, 2012
Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in SpainEva Poveda, Eugenia Vispo, Pablo Barreiro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 3, 2006
Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3Pablo Barreiro, Luz Martín-Carbonero, Marina Núñez, et al.
Antiviral Therapy|March 9, 2005
Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4Vincent Soriano, Marina Núñez, Matilde Sánchez-Conde, et al.
Antiviral Therapy|June 26, 2014
Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapiesPablo Labarga, Jose V Fernández-Montero, Mariola López, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 23, 2008
Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovirCarmen de Mendoza, Inmaculada Jiménez-Nacher, Carolina Garrido, et al.
Hepatology International|June 6, 2022
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in SpainJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|November 24, 2015
New hepatitis C therapies for special patient populationsVincent Soriano, Pablo Labarga, Carmen de Mendoza, et al.
Expert Opinion on Pharmacotherapy|May 6, 2016
Prevention and management of treatment failure to new oral hepatitis C drugsLaura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, et al.
Alimentary Pharmacology & Therapeutics|November 2, 2022
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in SpainJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Antiviral Therapy|August 5, 2008
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2bEugenia Vispo, Pablo Barreiro, Sonia Rodriguez-Nóvoa, et al.
Pageof 22